Search Bar & Filters
Found 79 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying MEN2312, a lysine acetyltransferase 6 KAT6 inhibitor, in adults with advanced breast cancer that is not curable. This first-in-human, phase 1 study evaluates MEN2312 alone and in combination with elacestrant to understand its safety and determine the best dose. Participants have specific genetic alterations in their tumors and have received prior endocrine therapy and cyclin-dependent kinase 4 and 6 inhibitor treatment. Participants will be randomly assigned to receive either MEN2312 by itself or MEN2312 combined with elacestrant, both given as oral tablets. The study follows a sequential design and aims to identify dose-limiting toxicities and recommend the phase 2 dose over several months of treatment. This includes monitoring drug levels in the body and how the body processes the medications. During the study, participants will have regular assessments to monitor side effects, tumor response, and overall health. These include evaluating the number of dose-limiting toxicities within the first 28 days and tracking response rates, progression-free survival, and overall survival for up to nine months after treatment ends. Researchers will also measure drug concentration and excretion to better understand the treatment effects and safety over time.
Actively Recruiting
Researchers are studying the safety and tolerability of NKX019, an investigational allogeneic CD19-directed CAR natural killer CAR NK cell therapy, in adults with autoimmune diseases. This Phase 12 open-label, multi-center, multi-cohort trial uses dose escalation and expansion to evaluate NKX019 in participants with conditions such as systemic sclerosis, idiopathic inflammatory myopathies, ANCA-associated vasculitis, and rheumatoid arthritis. The study aims to understand the treatments safety, preliminary effectiveness, pharmacokinetics, pharmacodynamics, and immunogenicity. Participants will undergo a cycle that starts with lymphodepletion using fludarabine and cyclophosphamide, or cyclophosphamide alone if they have low blood cell counts. This is followed by three doses of NKX019. The dose escalation follows a 33 design to find the recommended dose for further study. The study includes one treatment group receiving NKX019 combined with lymphodepleting drugs to assess safety and tolerability. During the study, participants will be closely monitored for dose-limiting toxicities within the first 28 days and treatment-emergent adverse events throughout treatment and 30 days after. Assessments include safety evaluations, pharmacokinetic measurements, and immunogenicity testing up to two years after infusion. The study also tracks effects on background therapies and disease-specific outcomes. Overall participation may last up to two years, with regular visits and evaluations to monitor health and treatment response.
Actively Recruiting
Researchers are evaluating a new treatment approach for adults aged 18 to 75 years with newly diagnosed acute myeloid leukemia AML that has specific genetic changes in the NPM1, MLLKMT2A, or NUP98 genes. This phase Ib trial aims to find the best dose and assess the safety of the drug revumenib SNDX-5613 when combined with standard chemotherapy drugs daunorubicin and cytarabine. The study focuses on patients who can tolerate intensive chemotherapy and have untreated AML. Participants receive revumenib orally twice daily alongside daunorubicin given intravenously for 1 to 3 days and cytarabine given as a continuous infusion or intermittent intravenous infusion depending on the treatment phase. Treatment includes an induction phase, possible re-induction for persistent disease, and consolidation cycles repeated every 42 days up to three times if tolerated. During treatment, patients undergo heart function scans, bone marrow biopsies, and blood tests at scheduled times to monitor response and safety. Throughout the study, patients are closely monitored through clinical assessments, including pharmacokinetic studies of revumenib and evaluations of leukemia cell response. After completing treatment, participants are followed for up to two years or until relapse or death. Researchers measure the recommended dose for further study, complete response rates, and other important outcomes such as measurable residual disease and potential biomarkers related to treatment response.
Actively Recruiting
Researchers are evaluating treatments for patients with accelerated or blast phase Philadelphia chromosome negative myeloproliferative neoplasms MPNs. This phase II trial compares ASTX727, a combination of cedazuridine and decitabine, given alone or combined with iadademstat. The study aims to assess how these treatments affect leukemia response rates and survival outcomes in patients who have not previously received certain DNA methyltransferase inhibitors. Patients are assigned to one of two groups. One group receives ASTX727 orally once daily on days 1 to 5 of each 28-day cycle. The other group receives the same ASTX727 schedule plus iadademstat orally on days 1-5, 8-12, 15-19, and 22-26 of each cycle. Treatment continues until disease progression or unacceptable side effects occur. Throughout the trial, researchers collect blood, buccal swab, and bone marrow samples to study the disease and treatment effects. Participants have regular assessments including blood tests, bone marrow biopsies, and sample collections over the treatment period. After stopping treatment for reasons other than disease progression, they are followed every 3 months if they stop due to progression, follow-up occurs every 6 months. The main outcome measured is the acute leukemia response rate within 4 treatment cycles. Secondary outcomes include event-free survival, overall survival, and the rate of stem cell transplantation over two years.
Actively Recruiting
Researchers are studying FMC-376 alone and combined with pembrolizumab in adults with advanced solid tumors that have the KRAS G12C mutation. This clinical trial includes three parts Phase 1A Dose Escalation, Phase 1B Dose Expansion, and Phase 2 Cohort Expansion. It aims to evaluate multiple dose levels and assess safety, pharmacokinetics, and clinical activity in participants with these tumors. Participants will receive FMC-376 orally daily in 21-day cycles, either as monotherapy or combined with pembrolizumab. The study progresses sequentially through dose escalation, dose expansion, and cohort expansion stages to find appropriate dosing and evaluate effects. Those receiving combination therapy must meet additional criteria related to immune health. Throughout the trial, participants will be closely monitored for dose limiting toxicities, adverse events, and overall response over approximately 24 months. Researchers will assess drug levels in blood, response duration, disease control, progression-free and overall survival. The study ensures safety and compliance by evaluating participants health status and organ function regularly.
Actively Recruiting
Researchers are evaluating how well amivantamab combined with lazertinib or with chemotherapy works in treating participants with epidermal growth factor receptor mutated EGFRm non-small cell lung cancer NSCLC, a common type of lung cancer. This Phase 2b study focuses on patients whose NSCLC is locally advanced or metastatic and who have specific EGFR mutations. The study aims to assess antitumor activity and treatment effects over time. Participants are assigned to one of two treatment groups. One group receives subcutaneous amivantamab combined with oral lazertinib in 28-day cycles, and the other group receives subcutaneous amivantamab combined with intravenous platinum-based chemotherapy carboplatin and pemetrexed in 21-day cycles. Treatment continues until disease progression, withdrawal, death, or investigator decision. The study is open-label and non-randomized, consisting of two parallel cohorts. During the study, participants will undergo regular assessments to monitor tumor response and safety. Key measures include progression-free survival tracked for up to 4 years and 6 months, along with evaluations of adverse events, overall survival, response rates, and duration of response. Researchers will also monitor dose changes and specific side effects such as venous thromboembolic events and dermatologic reactions. Participation may last several years depending on individual treatment and disease course.
Actively Recruiting
Researchers are evaluating whether donanemab, given as an intravenous infusion, can slow down the worsening of thinking, learning, memory, attention, and daily functioning in people with early cognitive decline and features of dementia with Lewy bodies. This phase 2 study focuses on participants aged 55 to 85 who show evidence of both amyloid and alpha-synuclein brain pathology. The trial is randomized and placebo-controlled to compare donanemab against a placebo. Participants will receive either donanemab or a placebo via IV infusion during the study. The treatment period lasts up to 52 weeks, during which various clinical and biomarker assessments will be conducted. The study includes monitoring for drug concentrations and immune responses. Both groups receive infusions under a quadruple-masked design to ensure unbiased results. Throughout the one and a half year participation, participants will be regularly evaluated using cognitive and functional tests like the Clinical Dementia Rating scale, Alzheimers Disease Rating Scales, and brain imaging to measure amyloid plaque levels. Safety assessments include monitoring for adverse effects and antibody development. Study partners familiar with the participants daily abilities provide additional information. The study aims to observe changes from baseline over the 52-week treatment period.
Actively Recruiting
Researchers are evaluating IBI363, a study drug, in adults with advanced solid cancers that have not responded to previous treatments. This Phase 2, open-label, multicenter trial aims to assess the drugs effectiveness, safety, and tolerability in people with melanoma, non-small cell lung cancer, colorectal cancer, and renal cell cancer. Participants will receive IBI363 as an intravenous infusion every two or three weeks. They will continue treatment until their disease worsens, they experience intolerable side effects, they choose to stop, the treatment duration reaches 24 months, or other reasons require stopping. The study does not include a placebo group and is open-label, meaning both researchers and participants know the treatment. During the study, participants will undergo regular assessments including monitoring of tumor response for up to two years and safety evaluations for adverse events up to 90 days after the last dose. Dose-limiting toxicities will be observed during specific time frames depending on the dosage schedule. Participants overall health and disease status will be closely followed throughout the trial period, which starts in April 2024 and ends in December 2026.
Actively Recruiting
Researchers are evaluating the safety and effects of the medicine Mevrometostat for treating RelapsedRefractory Small Cell Lung Cancer SCLC, Castration Resistant Prostate Cancer CRPC, and Follicular Lymphoma FL. This Phase 1 open-label study includes three parts, with Parts 1 and 2 closed for enrollment. Part 3, currently open, focuses on men with CRPC who have progressed after prior treatment. The study aims to understand how the study medicine behaves in the body and its impact on cancer. Participants in Part 3 receive Mevrometostat andor Enzalutamide. The study has two substudies a Bioequivalence BE substudy comparing two formulations of Mevrometostat, and a Drug-Drug Interaction DDI substudy with two cohorts. The BE substudy involves three single doses of Mevrometostat. The DDI substudy Cohort 1 takes Mevrometostat andor Itraconazole, and Cohort 2 combines Mevrometostat, Enzalutamide, and Itraconazole. After assessment phases, participants enter maintenance, taking Mevrometostat twice daily and Enzalutamide once daily until disease progression. Participants will visit the study center for dosing and monitoring, including evaluations of side effects, blood tests, and disease progression. The study measures dose-limiting toxicities, overall safety, and preliminary effectiveness using disease-specific criteria. Pharmacokinetics and patient-reported outcomes are also assessed at specific times. The study lasts approximately two years after the first participants visit, aiming to provide detailed safety and efficacy information.
Actively Recruiting
Researchers are evaluating the safety, tolerability, pharmacokinetics, and early anti-tumor effects of new drugs or drug combinations given around the time of surgery. This study focuses on adults with locally advanced but operable gastric, gastroesophageal junction, or esophageal adenocarcinoma who have not yet received treatment for their cancer. It is a Phase II, open-label study conducted at multiple centers, consisting of various sub-studies to test different treatment options. Participants will be assigned to specific sub-studies where they receive different combinations of investigational drugs such as Sonesitatug Vedotin, Rilvegostomig, Trastuzumab Deruxtecan T-DXd, and chemotherapy agents like 5-Fluorouracil, Capecitabine, and FLOT chemotherapy. Treatments include neoadjuvant therapy before surgery followed by adjuvant therapy after surgery, with dosing schedules defined per sub-study. Some drugs are given as intravenous infusions, while others like Capecitabine are taken orally. During the study, participants will have regular assessments including monitoring for adverse events and serious adverse events, evaluation of tumor response such as pathological complete response and tumor downstaging, and surgery completion rates. Researchers will also measure survival outcomes and drug levels in the blood. The study lasts up to 38 months per sub-study, including treatment and follow-up, to fully assess safety and preliminary effectiveness.
1-10 of 79
1